Moderna Collaborates with Generation Bio
Friday, March 24, 2023
Moderna and Generation Bio announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.
Under the terms of the agreement, Moderna advances two immune cell programmes, each of which will use a jointly developed ctLNP to deliver ceDNA. In addition, Moderna will advance two liver programmes, each of which uses a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA.
This collaboration, based on Generation Bio's non-viral genetic medicines platform, will have the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement. This partnership broadens the therapeutic pipeline and extend the potential benefits of nucleic acid therapy to more patients.
